Outcome of Board Meeting held on May 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board approved standalone and consolidated audited financial results for Q4 and FY ended March 31, 2025, with the auditor issuing an unmodified (clean) opinion on both. Standalone revenue from operations nearly doubled to Rs. 2,759.27 lakhs (vs Rs. 1,405.78 lakhs in FY24), and standalone net profit more than doubled to Rs. 166.39 lakhs (vs Rs. 74.45 lakhs), with EPS rising to Rs. 8.98. Consolidated revenue grew strongly to Rs. 3,270.29 lakhs, but consolidated net profit declined to Rs. 75.07 lakhs (vs Rs. 106.49 lakhs) due to a Rs. 38.84 lakh loss share from associate Neuro and Spine Associates. Q4 standalone net profit fell sharply to Rs. 5.06 lakhs and consolidated Q4 swung to a loss of Rs. 61.52 lakhs. Both standalone and consolidated operating cash flows remained negative at Rs. (35.07) lakhs and Rs. (113.05) lakhs respectively.
Strong topline growth and clean audit opinion are positives, but the sharp Q4 profit drop, consolidated FY PAT decline, and continued negative operating cash flows raise concerns about earnings quality and the drag from the associate investment. Shareholders should watch for sustained improvement in cash generation and consolidation outcomes.